Predictive markers of response and toxicity to tarlatamab in patients with extensive stage small cell lung cancer (ES-SCLC): A multi-institutional real-world analysis.
Graeme Fenton, Daniel Hess, Annie Zhang, Wanru Guo et autres
8097 Background: Tarlatamab (tarla) is a novel immunotherapeutic agent for the treatment of relapsed ES-SCLC associated with favorable response and survival outcomes. While tarla’s unique side effect profile of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) is well …
us (code pays fourni par la source)
1 citation
Journal of Clinical Oncology